Adult patients with schizophrenia treated with lurasidone HCl tablets (Latuda, Sunovion Pharmaceuticals) had minimal weight gain and metabolic changes, according to the results from a new pooled data analysis of short- and long-term studies, which were presented at the Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii.
Adult patients with schizophrenia treated with lurasidone HCl tablets (Latuda, Sunovion Pharmaceuticals) had minimal weight gain and metabolic changes, according to the results from a new pooled data analysis of short- and long-term studies, which were presented at the Annual Meeting of the American Psychiatric Association in Honolulu, Hawaii.
“The study is pertinent as the effects of antipsychotics on weight gain and metabolic parameters in patients with schizophrenia is a common area of concern for both patients and clinicians-and a driver of cost for managed care plans,” Antony Loebel, MD, executive vice president, clinical research and medical affairs at Sunovion Pharmaceuticals, told Formulary.
“The comprehensive database analysis we conducted highlights Latuda's potential for low rates of weight gain and associated metabolic disturbances in both short and longer-term use. We will continue to evaluate the effect of Latuda in these areas in our ongoing clinical trials and based on our post-marketing safety surveillance activities,” Dr Loebel said.
The short-term data were pooled from 7 double-blind, placebo-controlled, 6-week studies in patients with schizophrenia. In this analysis, patients treated with lurasidone (once-daily doses of 20 mg to 160 mg) experienced, on an overall basis, low rates of weight gain and metabolic changes. The results for the pooled analysis of short-term study data were as follows:
* Weight*: +0.43 kg for lurasidone (n=1486); -0.02 for placebo (n=696)
* Clinically significant weight gain (≥7%): 4.8% for lurasidone (n=1486); 3.3% for placebo (n=696)
* Total cholesterol**: -5.0 mg/dL for lurasidone (n=1419); -5.0 for placebo (n=660)
* Triglycerides**: -4.0 mg/dL for lurasidone (n=1419); -6.0 for placebo (n=660)
* Glucose**: 0.0 mg/dL for lurasidone (n=1453); 0.0 mg/dL for placebo (n=680)
*As measured by mean LOCF end point change
** As measured by median LOCF end point change
“The potential effect of antipsychotic use on metabolic parameters in patients with schizophrenia is an area of concern for clinicians and the research community,” said Antony Loebel, MD, executive vice president, clinical research and medical affairs at Sunovion.
“We are encouraged by the results of this comprehensive database analysis and will continue researching the effect of Latuda on weight and metabolic disturbance in short- and longer-term treatment.”
Longer-term (ranging from 6 to 22 months) open-label treatment data were also included in this pooled analysis. The pooled analysis showed that change from baseline at month 12 on weight and various metabolic parameters for lurasidone-treated patients versus placebo were:
* Weight: -0.73 kg (mean) (n=377)
* Body mass index (BMI): -0.25 kg/m2 (mean) (n=377)
* Total cholesterol: -2.0 mg/dL (median) (n=307)
* Triglycerides: -5.0 mg/dL (median) (n=307)
* Glucose: +1.0 mg/dL (median) (n=307)
Lurasidone is an atypical antipsychotic that was FDA approved in October 2010 for the treatment of schizophrenia. The 160 mg/day dose has not been reviewed or approved by FDA.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.